Longitude gets some latitude in 'brutal' climate as it builds new $375m fund
This article was originally published in Scrip
Longitude Capital has collected $331.6 million from limited partners for an anticipated $375 million venture capital fund in a fundraising environment that managing director Patrick Enright described only as "brutal".
You may also be interested in...
Gene editing is all the rage in biotechnology these days, but Caribou Biosciences Inc. has taken a different path than its CRISPR peers by diversifying beyond therapeutics to agriculture, industrial and applied research. The company also has taken a different financing path – recently closing a $30m Series B venture capital round instead of pursuing an initial public offering.
Clinical trials in a range of diseases continue to be impacted by concerns about patient safety and health care resources as the COVID-19 pandemic grows.
ReCode, whose platform allows for organ-specific delivery of RNA therapies, plans to start clinical trials in 2022 for its two lead programs in primary ciliary dyskinesia and cystic fibrosis.